We are live on ! Find out more

GRAL

GRAIL Inc

GRAL

Market cap $3.59B

80.34 USD

-0.28

0.35%

At close Updated Sep 4, 4:00 PM EDT

Pre-market

After hours

80.51

+0.17

0.21%

1 day

-0.35%

5 days

1.7%

1 month

10.51%

3 months

20.72%

6 months

48.67%

Year to date

-9.6%

1 year

139.18%

5 years

488.14%

10 years

488.14%

About: GRAIL Inc is a healthcare company focused on developing technologies for early cancer detection. The company has developed a multi-cancer early detection blood test that has the ability to detect all types of cancer, across all stages. It operates in one reportable operating segment which provides multi-cancer early detection testing and service.

Employees: 910

Healthcare Diagnostics & Research

News

Positive

Neutral

Negative

Sentiment 3-Months

Positive 2.2%

Neutral 97.2%

Negative 0.6%

The Motley Fool

Grail Stock Jumps in August as FDA Schedules a Key Meeting for its Galleri Cancer Test

FDA approval is crucial for Galleri's adoption by insurers. The company received some good news from the FDA, and a pivotal meeting is coming up for Grail's Galleri test.

Grail Stock Jumps in August as FDA Schedules a Key Meeting for its Galleri Cancer Test

GRAIL Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

SUNNYVALE, Calif., Sept. 3, 2026 /PRNewswire/ -- GRAIL, Inc. (Nasdaq: GRAL), a healthcare company whose mission is to detect cancer early when it can be cured, today announced that it has granted equity awards in the form of restricted stock units ("RSUs") underlying an aggregate of 55,867 shares of GRAIL's common stock to 59 recently hired non-executive employees as an inducement material to their acceptance of employment with GRAIL.

GRAIL Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

GRAIL to Present at Morgan Stanley's 24th Annual Global Healthcare Conference

MENLO PARK, Calif., Aug. 31, 2026 /PRNewswire/ -- GRAIL, Inc. (Nasdaq: GRAL), a healthcare company whose mission is to detect cancer early when it can be cured, today announced that company management will present at the Morgan Stanley 24th Annual Global Healthcare Conference in New York on Monday, Sep. 14 at 11:30 a.m.

GRAIL to Present at Morgan Stanley's 24th Annual Global Healthcare Conference

GRAIL Highlights Galleri Growth Ahead of Key FDA Advisory Meeting

GRAIL NASDAQ: GRAL Chief Financial Officer Aaron Freidin said the company's Galleri multi-cancer early detection test recorded strong first-half growth as it expanded distribution through digital health platforms, employers and physician offices.

GRAIL Highlights Galleri Growth Ahead of Key FDA Advisory Meeting

GRAIL: Looking Beyond The NHS-Galleri Headline

GRAIL faces a binary FDA approval event for Galleri, with significant stock movement expected based on the outcome. Despite disappointing NHS-Galleri trial results, I believe the true value of the test would have been apparent with a longer monitoring period. While GRAL has a solid cash position, commercialization delays could see the company having to raise a large amount of capital on unfavorable terms.

GRAIL: Looking Beyond The NHS-Galleri Headline

FDA Panel Schedules to Evaluate GRAIL Premarket Approval Application for Multi-Cancer Early Detection Test

GRAIL Inc. (NASDAQ:GRAL) on Friday said it is preparing for a pivotal regulatory event as the U.S. Food and Drug Administration's (FDA) Molecular and Clinical Genetics Panel gears up to evaluate the healthcare company's flagship cancer diagnostic tool.

FDA Panel Schedules to Evaluate GRAIL Premarket Approval Application for Multi-Cancer Early Detection Test

US FDA to hold advisory meeting to review Grail's multi-cancer test

Grail said on Friday the U.S. FDA plans to hold a ‌meeting of outside experts to review its multi-cancer screening test Galleri in September, sending its shares up 4% in morning ⁠trade.

US FDA to hold advisory meeting to review Grail's multi-cancer test

GRAIL Announces FDA Advisory Committee Meeting to Review Premarket Approval Application for the Galleri® Multi-Cancer Early Detection Test

MENLO PARK, Calif., Aug. 7, 2026 /PRNewswire/ -- GRAIL, Inc. (Nasdaq: GRAL), a healthcare company whose mission is to detect cancer early when it can be cured, today announced that the U.S. Food and Drug Administration's (FDA) Molecular and Clinical Genetics Panel of the Medical Devices Advisory Committee is scheduled to meet on Sept.

GRAIL Announces FDA Advisory Committee Meeting to Review Premarket Approval Application for the Galleri® Multi-Cancer Early Detection Test

GRAIL, Inc. (GRAL) Q2 2026 Earnings Call Transcript

GRAIL, Inc. (GRAL) Q2 2026 Earnings Call Transcript

GRAIL, Inc. (GRAL) Q2 2026 Earnings Call Transcript

GRAIL Q2 Earnings Call Highlights

GRAIL NASDAQ: GRAL reported second-quarter revenue growth driven by higher Galleri test volumes, while outlining continued efforts to secure FDA approval, expand its commercial organization and build international distribution partnerships.

GRAIL Q2 Earnings Call Highlights

See News Rankings

Price charts implemented using Lightweight Charts™